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Objectives: To assess the medication adherence rates and quality of life in 
Rheumatoid Arthritis (RA) patients. MethOds: RA patients admitted in the 
general medicine ward of a tertiary care hospital in Karnataka, India, during 
August to December 2013 were enrolled in the study. Demographic data of these 
patients was collected from patients’ medical records, outpatient data and by 
interviews. Patients (age≥ 18 years) with RA, irrespective of sex, fulfilling the 2010 
ACR/EULAR Classification Criteria, were enrolled in the study. Patient’s assessment 
of adherence to medication was analyzed by using Medication Adherence Report 
Scale (MARS) and physical function using the Kannada version of the Stanford 
Improved Health Assessment Questionnaire (KA-HAQ) was collected. Results: 
The mean age of 72 RA patients was 46.90 ± 12.88 years and disease durations was 
4.27 ± 5.53 years. 86% of the patients were females. Among patients, 15 (21.43%) 
received methotrexate alone and 28 (40%) received a combination therapy of 
methotrexate and hydroxychloroquine. The mean KA-HAQ score of RA patients 
measured by KA-HAQ was 2.70 ± 1.01. Scores on MARS ranged from 26 to 41 with a 
mean score of 38.65 ± 3.5. The Cronbach’s alpha for the MARS was 0.6 and KA-HAQ 
was 0.92.Using the mean cut-point 44% of 68 patients who completed the MARS 
were adherent and remaining 64% were not adherent. cOnclusiOns: In our study 
we found that 64% of the patients were not adherent to the medications which 
lead to decreased quality of life RA patients. Adherence to the medications is the 
optimal management for RA.
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Objectives: Purpose of the study was to determine kinematic difference 
between overground and treadmill walking. MethOds: A total of 30 healthy 
men, 30 healthy female aged 19-23 participated in the study. Inclusion criteria 
in the study were that participants no low back and lower extremity pain, no 
traumatic injury and foot deformities. Participants walked at their preferred 
velocity on overground. The treadmill velocity was adjusted average velocity 
obtained in overground walking. Walking in two conditions was captured by high 
speed camera and analyzed by motion analyses software. Results: In com-
parison between treadmill and overground walking was significantly different. 
Maximum hip flexion angle (P< 0.017), maximum),maximum knee flexion (0.033)
maximum ankle dorsiflexion (P< 0.028) and maximum ankle planterflexion 
(P< 0.044) were significantly different in the two conditions. In the male, maximum 
hip flexion (P< 0.020), maximum knee flexion (P< 0.019), maximum ankle dorsi-
flexion (P< 0.018) ) were significantly different in the two conditions. For female, 
maximum hip flexion (P< 0.015), maximumankle dorsiflexion (P< 0.045), maximum 
plan terflexion (P< 0.021) were significantly different in the two conditions. 
Overground walking male of knee extension was associated with body mass 
(r= -411, p< 0.05), hip flexion was associated with body height (r= 0.433, p< 0.05). 
Overground walking female of knee flexion was associated with body mass dur-
ing (r= 0.469, p< 0.05), ankle dorsiflexion was associated with height (r= 0.443, 
p< 0.05). Treadmill walking in female, hip extension (r= -0.542, p< 0.05), knee flexion 
(r= -0.342, p< 0.05), ankle dorsiflexion (r= -0.469, p< 0.05) was associated with body 
mass.Hip extension was associated with height (r= -0.542, p< 0.05). cOnclusiOns: 
The study revealed significantly kinematic difference between overground and 
treadmill walking.
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Objectives: Patellofemoral pain syndrom is a common problem experienced 
by active adults and adolescents. Ascending stairs is one of the most painful 
activities of daily living in person with patellofermoral pain syndrome. However, 
its etiology has remained vague and is controversial. Nevertheless previous stud-
ies were reported from either the viewpoint of kinematics of the knee joint or 
hip muscle weakness, and is unclear whether hip and knee muscle weakness 
affect on knee medial displacement during physical acitvities. of the this study 
was to determine relationship between hip muscle strength and kinematics of 
the knee joint. MethOds: Forty healthy subjects participated in this study. The 
knee medial displacement was measured during a functional tests using two 
high speed cameras. Images of videos were processed using motion analysis 
software. Peak isometric muscle strengths of the following muscles were meas-
ured hip abductors, hip adductors, hip external rotators, hip internal rotators, 
knee extensors and knee flexors. Hip and knee muscle strengths were measured 
using a hand held dynamometer as isometric muscle strength referring to Katoh’s 
method. Results: Muscle strength of hip external rotators was associated with 
knee medial displacement during both single leg squatting (r= - 0.519, P< 0.001) 
and dropping (r= -0.520, P< 0.001). cOnclusiOns: The present results suggest 
that hip muscles’ strength, particularly hip external rotators’ strength are closely 
associated with knee medial displacement.
Objectives: A phase III clinical trial demonstrated the advantage of denosumab 
over zoledronic acid(ZA) in delaying the first on-study and subsequent skeletal-
related events(SREs) in patients with prostate cancer(PC). Recently, generic ZA 
became available. The purpose of this study was to examine the cost-effectiveness 
of denosumab vs. brand or generic ZA in the prevention of SREs in Kazakhstani 
patients with PC. MethOds: An excel-based Markov model was constructed with 
4-week model cycles to analyse the cost-effectiveness of the treatments from the 
perspective of Ministry of Health with a 10-year time horison for PC cohort. Direct 
costs(in 2014 tenge) included costs of drug, adverse event and SRE(pathologic frac-
ture, surgery to bone, radiation to bone, spinal cord compression) treatment. A dis-
count rate of 3% per year was applied. Effectiveness was appraised based on the 
number of SREs. The health states were defined according to SRE occurance,SRE 
history and death. The model assumed that a maximum of 1 SRE could occur in 
each cycle. Transition probabilities were derived from the relevant phase III trials. 
Results were present in the incremental total cost per SRE avoided. One-way sensi-
tivity analyses were performed to examine the robustness of the model. Results: 
Over 10-year period, denosumab incurred 103091 tenge higher costs than brand 
ZA, 677133 tenge higher costs than generic ZA, 0.58 fewer SREs per PC patient; The 
estimated incremental total direct costs per SRE avoided with the use of denosumab 
were 177743 tenge (instead of brand ZA) and 1167470 tenge (instead of generic ZA). 
Results were robust to one-way sensitivity analyses. cOnclusiOns: With assump-
tion that brand and generic ZAs are equally effective, denosumab seems to be supe-
rior alternative for brand ZA (insignificant difference in costs), and costly alternative 
for generic ZA from a perspective of Ministry of Health of Republic of Kazakhstan.
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Objectives: To evaluate the cost-utility of Infliximab plus methotrexate (MTX) com-
pared with MTX alone, in severe rheumatoid arthritis (RA) patients who were intol-
erant or inadequately responded to conventional DMARDs including MTX which is 
available in the national list of essential medicine (NLEM) in Thailand. MethOds: 
A Markov model consisting of Markov states defined by the disease activity score 
28 (DAS28) was developed to reflect the clinical assessment in the treatment of RA 
in Thailand. Markov states for remission (DAS < 2.6), low disease activity (DAS 2.6-
3.2), moderate disease activity (DAS 3.2-5.1), high disease activity (DAS ≥ 5.1), and 
dead were defined. With a cycle length of 6 months, transition probabilities were 
estimated based on ACR response in the clinical trial which was assumed to directly 
represent changes in disease severity. DAS28 was assumed to be a clinically appro-
priate proxy for utility estimation (EQ5D). Both direct and indirect costs including 
patient’s income loss were calculated under societal perspective. Data source of 
resource use are mainly based on estimation by experts. Cost and outcomes were 
discounted at 3%. One-way and probabilistic sensitivity analysis were conducted 
to test the robustness of the results. Results: Infliximab plus MTX had an ICER of 
131,867 baht per QALY gained compared to MTX alone. This falls into the range of 
acceptable ICER within 1-3 times of GDP per capita in Thailand (120,000 – 360,000 
baht per QALY gained). The probability of cost-effective for Infliximab was presented 
at 8%, 50%, and 70% at the willingness-to-pay of 120,000 baht, 240,000 baht, and 
360,000 baht per QALY gained respectively. cOnclusiOns: This model suggests, 
with its underlying assumption, that Infliximab plus MTX seems to be more cost-
effective treatment than MTX alone for Thai patients with severe RA that cannot 
be controlled by conventional DMARDs.
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Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease charac-
terized by inflammation and destruction of the joints often resulting in a signifi-
cant impact on quality of life. There are limited studies estimating the resource 
utilization of RA patients using real-world data in Taiwan. This study aimed to 
estimate the direct health care utilization in Taiwanese RA patients. MethOds: 
We performed a retrospective database analysis using 2011 data from the National 
Health Insurance Research Database (NHIRD) in Taiwan, a claims-based database 
covering over 99% of the population. We estimated the annual incremental health 
care utilization of RA patients compared with a control cohort matched 1:4 on 
demographics and clinical covariates. Health care resources were evaluated for 
the following categories: surgeries, medications, ward use, medical materials and 
devices (MMDs), and lab tests. The percentage of patients partaking in a health 
care utilization category was calculated as the number of patients with the spe-
cific claim divided by the total number of patients in the cohort. Results: The 
total number of RA patients was 41,269. Females made up 78% of the cohort and 
the mean age was 59.4 years (SD= 15.5). The average history of RA was 5.6 years 
(SD= 2.7). When comparing RA to non-RA patients, drug utilization had some of 
the largest differences. RA patients had used traditional disease-modifying anti-
rheumatic drugs (TDMARDs), biologic DMARDs (BDMARDs), NSAIDs, and steroids 
at a rate of 70.8%, 13.2%, 64.8% and 52.8% respectively. For surgeries, lab tests, and 
MMDs, the highest incremental differences were cataract surgeries, immunology 
examination, and orthopedic replacements. cOnclusiOns: Direct health care 
utilization of RA was substantial in Taiwan. The NHIRD provides a comprehensive 
source for estimating the incremental resource utilization of RA versus non-RA 
patients. This study provides a key piece of information to estimate the burden 
of the RA illness in Taiwan.
